Edmond DE Rothschild Holding S.A. Has $14.66 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Edmond DE Rothschild Holding S.A. grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 1.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 74,624 shares of the medical research company’s stock after purchasing an additional 962 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in IQVIA were worth $14,664,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in IQV. Vanguard Group Inc. boosted its stake in IQVIA by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock valued at $3,956,087,000 after purchasing an additional 105,504 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock worth $481,380,000 after buying an additional 59,426 shares in the last quarter. Cantillon Capital Management LLC boosted its position in shares of IQVIA by 12.3% in the fourth quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock valued at $406,018,000 after acquiring an additional 226,017 shares during the period. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares in the last quarter. Finally, Norges Bank bought a new position in IQVIA during the fourth quarter worth about $336,041,000. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IQV shares. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Barclays lowered their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Robert W. Baird cut their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Finally, Stifel Nicolaus cut their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Price Performance

Shares of NYSE:IQV opened at $177.27 on Monday. The firm has a market cap of $31.25 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52 week low of $176.03 and a 52 week high of $253.84. The firm’s fifty day moving average is $193.15 and its 200-day moving average is $206.05. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.